Great Lakes Advisors LLC Buys 98,190 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• Great Lakes Advisors LLC increased its stake in Halozyme Therapeutics by 153.2%, acquiring 98,190 shares and now owns approximately 0.13% of the company, valued at $10.36 million.
• Halozyme Therapeutics reported a strong quarterly performance with $1.54 earnings per share, surpassing estimates and demonstrating a year-over-year revenue growth of 40.8%.
• Analysts have mixed ratings for Halozyme, with recent upgrades pushing the price target to as high as $91, reflecting a positive outlook despite some analysts maintaining a "hold" or "sell" rating.

Great Lakes Advisors LLC grew its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 153.2% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 162,288 shares of the biopharmaceutical company's stock after acquiring an additional 98,190 shares during the period. Great Lakes Advisors LLC owned about 0.13% of Halozyme Therapeutics worth $10,356,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of HALO. Penserra Capital Management LLC bought a new position in Halozyme Therapeutics in the first quarter worth approximately $125,000. Bessemer Group Inc. raised its stake in Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 207 shares in the last quarter. Fifth Third Bancorp raised its stake in Halozyme Therapeutics by 29.4% in the first quarter. Fifth Third Bancorp now owns 10,017 shares of the biopharmaceutical company's stock worth $639,000 after buying an additional 2,276 shares in the last quarter. GAMMA Investing LLC raised its stake in Halozyme Therapeutics by 199.0% in the first quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company's stock worth $179,000 after buying an additional 1,865 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its stake in Halozyme Therapeutics by 620.5% in the first quarter. Farther Finance Advisors LLC now owns 5,505 shares of the biopharmaceutical company's stock worth $341,000 after buying an additional 4,741 shares in the last quarter. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $75.85 on Tuesday. The business's fifty day simple moving average is $63.28 and its 200-day simple moving average is $59.97. The company has a market cap of $8.87 billion, a PE ratio of 17.36, a PEG ratio of 0.41 and a beta of 1.19. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $76.28.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The business had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. During the same period in the prior year, the firm posted $0.91 earnings per share. The business's quarterly revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total value of $1,270,200.00. Following the transaction, the chief executive officer directly owned 733,719 shares of the company's stock, valued at $46,598,493.69. This represents a 2.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bernadette Connaughton sold 4,000 shares of the company's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total value of $294,720.00. Following the completion of the transaction, the director directly owned 46,952 shares in the company, valued at approximately $3,459,423.36. The trade was a 7.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 104,000 shares of company stock worth $6,316,120. 2.90% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

HALO has been the subject of a number of recent research reports. Morgan Stanley boosted their price objective on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an "overweight" rating in a research note on Monday, August 18th. JMP Securities boosted their price objective on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a research note on Wednesday, August 6th. Zacks Research raised shares of Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 2nd. Leerink Partnrs downgraded shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. Finally, HC Wainwright upped their price target on Halozyme Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Halozyme Therapeutics has a consensus rating of "Hold" and a consensus target price of $67.11.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.